Imagine diagnosing one of the most challenging neurological diseases with just a quick finger-prick, a few drops of blood and a test sent in the post. This may sound like science fiction, but we are hoping our research could soon help it become a reality.

Our team at the UK Dementia Research Institute’s Biomarker Factory at UCL are part of the global effort working to develop and validate a test for Alzheimer’s disease. We’re currently working to overcome the various technical challenges facing these tests so that this test can one day soon be available to the broader public.

At their core, these finger-prick tests are designed to detect specific biomarkers.
Biomarkers are biological molecules found in the blood which indicate signs of disease. In the case of Alzheimer’s disease, the brain gradually accumulates abnormal proteins. These proteins form structures such as amyloid plaques and tau tangles which damage the brain’s neural networks. They’re also involved in brain inflammation.

These abnormal proteins can be detected in the brain, cerebrospinal fluid and, importantly, the blood years before symptoms arise.

Recently, research has also shown these biomarkers can be measured in dried blood samples from a simple finger-prick. A study focusing on 337 people showed that these dried blood samples can reliably detect Alzheimer’s-related changes in biomarkers with a diagnostic accuracy of around 86% compared to conventional methods.

Once refined and validated, these tests could aid with early detection, screening at-risk people, tracking disease progression or even evaluating the effectiveness of emerging........

© The Conversation